Business Wire

Tilray® Exports First Shipment of Medical Cannabis to Spain

4.2.2021 14:00:00 EET | Business Wire | Press release

Share

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech ("Worldpharma"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17th country to receive Tilray medical cannabis worldwide.

The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain. With Tilray's pharmaceutical-grade cannabis, Worldpharma will develop medical cannabis products for clinical trials in Spanish Hospitals for diseases such as Alzheimer's, Parkinson’s disease, and skin inflammation.

Brendan Kennedy, Tilray’s Chief Executive Officer, said, “We’re incredibly honored to be the first cannabis company to be approved and to ship medical cannabis into Spain. As we continue to work with regulators around the world, we are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.”

Juan Jose Garcia Miquel, Founder of World Pharma Biotech, said, "We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP certified products that meet the highest of E.U. and Spanish Pharmacology Standards. We intend to work with the companies with the highest quality pharmaceutical standards to give doctors and patients total confidence. It's been impossible to reach this level of quality from other cannabis authorized companies in Spain.”

Sascha Mielcarek, Tilray’s General Manager for Europe, said, “We are very pleased to partner with Worldpharma. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need, paving the way for future medical cannabis standards of care.”

Tilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.

Tilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.

About WorldPharma Biotech

World Pharma Biotech was founded in 2014 in Valencia, Spain, focused on vegetal ingredients for nutraceuticals, cosmetics, and pharmaceutical industries. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and Start-up companies from Valencia University. The extraction and purification lab's primary focus is the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading "Risk Factors" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:
Tilray Global:
Berrin Noorata
news@tilray.com

To request an interview opportunity:
Media
Amy Bonwick
647-515-3748
amy@pomppr.com

Ranjit Dhatt
647-890-2445
ranjit@pomppr.com

Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 16:45:00 EET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 16:39:00 EET | Press release

Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real capacity. Factbird is a System of Action, built for manufacturers who have plenty of data and struggle to act on it. It connects production data from every line, machine, and operator

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 16:17:00 EET | Press release

Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candidates designed to target the underlying biology of canine aging and help dogs live longer, healthier lives alongside the people who love them. LOY-003 i

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 16:08:00 EET | Press release

NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115196647/en/ NIKE, Inc. is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. Elite marathoners. Backyard hoopers. An athlete* walking into the gym for the first time. Every athlete NIKE, Inc. works alongside pushes the company to imagine what doesn’t yet exist, then make those possibilities real. Today, NIKE, Inc. is showing what comes next. As part of its World of Athletes* showcase in Beaverton, Ore., the company is unveiling Tuned Air, the next frontier of Nike Air; new Nike Mind and Nike Free footwear, platforms built to scale across sport; innovation

Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release

Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye